BioCryst Pharmaceuticals Has Collaborated With Er-kim Pharmaceuticals To Commercialize Orladeyo (Berotralstat), To Prevent Attacks Of Hereditary Angioedema, In Turkey
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals has partnered with Er-kim Pharmaceuticals to commercialize Orladeyo (Berotralstat), a drug used to prevent attacks of hereditary angioedema, in Turkey.
July 19, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst Pharmaceuticals' partnership with Er-kim Pharmaceuticals to commercialize Orladeyo in Turkey could potentially increase its market reach and revenue.
The partnership with Er-kim Pharmaceuticals allows BioCryst to expand its market for Orladeyo into Turkey. This could potentially increase the company's revenue and profitability, which may positively impact its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100